Top Markets
Coin of the day
Oruka Therapeutics, Inc. Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc.

ORKA
Rang in Aktien #3143
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Aktienkurs
$100.91
Zuletzt synchronisiert: 2026-08-25
Marktkapitalisierung
$6.09B
Veränderung (1 Tag)
-1.47%
Veränderung (1 Jahr)
581.36%
Land
US
Handel Oruka Therapeutics, Inc. (ORKA)

Kategorie

Dividendenrendite-Verlauf für Oruka Therapeutics, Inc. (ORKA)
Dividendenrendite (TTM) von Oruka Therapeutics, Inc. (Aktienkürzel: ORKA) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Oruka Therapeutics, Inc. (ORKA) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
Unternehmen Dividendenrendite Land
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH